Editas Medicine Lead Therapy Cuts LDL Cholesterol by 90% in Preclinical Study

MT Newswires Live05-14

Editas Medicine (EDIT) said Thursday that preclinical data for its lead therapy, EDIT-401, reduced LDL cholesterol by an average of 90% across all dose groups in on-human primates, supporting its development as a potential treatment of hyperlipidemia.

The drug developer said the treatment achieved the reduction with moderate editing of LDLR alleles and a sixfold increase in liver LDLR protein levels.

The cholesterol-lowering effect appeared quickly and remained durable for about six months, the company said.

Editas said studies in mice suggested dose adjustments may not be necessary to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635716508?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 18:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635716508","market":"hk","top_or_hot":-1,"title":"Editas Medicine Lead Therapy Cuts LDL Cholesterol by 90% in Preclinical Study","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/EDIT\">Editas Medicine</a> (EDIT) said Thursday that preclinical data for its lead therapy, EDIT-401, reduced LDL cholesterol by an average of 90% across all dose groups in on-human primates, supporting its development as a potential treatment of hyperlipidemia.</p><p>The drug developer said the treatment achieved the reduction with moderate editing of LDLR alleles and a sixfold increase in liver LDLR protein levels.</p><p>The cholesterol-lowering effect appeared quickly and remained durable for about six months, the company said.</p><p>Editas said studies in mice suggested dose adjustments may not be necessary to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Editas Medicine Lead Therapy Cuts LDL Cholesterol by 90% in Preclinical Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEditas Medicine Lead Therapy Cuts LDL Cholesterol by 90% in Preclinical Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-14 18:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/EDIT\">Editas Medicine</a> (EDIT) said Thursday that preclinical data for its lead therapy, EDIT-401, reduced LDL cholesterol by an average of 90% across all dose groups in on-human primates, supporting its development as a potential treatment of hyperlipidemia.</p><p>The drug developer said the treatment achieved the reduction with moderate editing of LDLR alleles and a sixfold increase in liver LDLR protein levels.</p><p>The cholesterol-lowering effect appeared quickly and remained durable for about six months, the company said.</p><p>Editas said studies in mice suggested dose adjustments may not be necessary to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LDL","symbol_name":"莱德尔","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635716508","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635716508","pubTimestamp":1778755255,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Editas Medicine (EDIT) said Thursday that preclinical data for its lead therapy, EDIT-401, reduced LDL cholesterol by an average of 90% across all dose groups in on-human primates, supporting its deve","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LDL":"莱德尔","EDIT":"Editas Medicine, Inc.","BK4139":"生物科技","BK4556":"基因编辑","DBB":"基础金属ETF-PowerShares"},"translate_title":"Editas Medicine领先疗法在临床前研究中将LDL胆固醇降低90%","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LDL":1.5,"EDIT":1.5,"DBB":1.5},"content_text":"Editas Medicine (EDIT) said Thursday that preclinical data for its lead therapy, EDIT-401, reduced LDL cholesterol by an average of 90% across all dose groups in on-human primates, supporting its development as a potential treatment of hyperlipidemia.The drug developer said the treatment achieved the reduction with moderate editing of LDLR alleles and a sixfold increase in liver LDLR protein levels.The cholesterol-lowering effect appeared quickly and remained durable for about six months, the company said.Editas said studies in mice suggested dose adjustments may not be necessary to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635716508","isCrawlerRequest":true}